What is it about?
Tocilizumab is an anti-IL-6 receptor monoclonal antibody approved for the treatment of various autoimmune diseases. Tocilizumab has been also used for the treatment of sarcoidosis. This is a report of an 80-year-old man who developed cutaneous sarcoidosis during treatment with Tocilizumab.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
We bring this rare paradoxical reaction to the attention of dermatologists, rheumatologists and other practicing clinicians so that they can be aware of this potential side effect. IL6-inhibitor-induced sarcoidosis-like reaction should be considered in the differential diagnosis when evaluating a new skin rash in an individual treated with IL-6 inhibitors.
Perspectives
Induction of sarcoidosis in patients treated with IL-6 inhibitors is problematic since this agent has also been used for the treatment of sarcoidosis.
Dr Grigorios Theodosiou
Region Skane
Read the Original
This page is a summary of: Tocilizumab‐induced sarcoidosis‐like reaction in a patient with giant cell arteritis. Clinical implications of a paradoxical phenomenon, International Journal of Dermatology, May 2020, Wiley,
DOI: 10.1111/ijd.14909.
You can read the full text:
Contributors
The following have contributed to this page
